The effects of Xanthigen in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat.
OBJECTIVE
To investigate the effects of Xanthigen (brown marine algae fucoxanthin + pomegranate seed oil (PSO)) on body weight, body fat, liver lipids, and blood biochemistry; and Xanthigen and its individual components on resting energy expenditure (REE) in obese, non-diabetic female volunteers with non-alcoholic fatty liver disease (NAFLD) and normal liver fat (NLF) content.


METHODS
Sixteen-week, double-blind, randomized, placebo-controlled study. Food record data, body composition, REE (only 41 volunteers with NAFLD) and blood sample analysis were assessed weekly for 16 weeks in 151 non-diabetic, obese premenopausal women with liver fat content above 11% (NAFLD) n = 113, and below 6.5% (NLF) n = 38.


RESULTS
Xanthigen-600/2.4 mg (300 mg PSO + 300 mg brown seaweed extract containing 2.4 mg fucoxanthin) resulted in statistically significant reduction of body weight (5.5 +/- 1.4 kg NAFLD group and 4.9 +/- 1.2 kg NLF group, p < 0.05), waist circumference (NAFLD group only), body (3.5 +/- 1.9 kg NAFLD group, p < 0.001; 3.6 +/- 0.7 kg NLF group, p < 0.05) and liver fat content, liver enzymes (NAFLD group only), serum triglycerides and C-reactive protein. Weight loss and reduction in body and liver fat content occurred earlier in patients with NLF than in patients with NAFLD. Fucoxanthin (> 2.4 mg) and Xanthigen-400/1.6 mg (200 mg PSO + 200 mg brown seaweed extract containing 1.6 mg fucoxanthin) significantly increased REE in NAFLD subjects compared to placebo.


CONCLUSIONS
Xanthigen promoted weight loss, reduced body and liver fat content, and improved liver function tests in obese non-diabetic women. Xanthigen and Fucoxanthin also increased REE. This product may be considered a promising food supplement in the management of obesity.
Institute of Immunopathology, Russian Academy of Natural Sciences, Moscow, Russia. abidovmusa@gmail.com
M
M
Abidov
Z
Z
Ramazanov
R
R
Seifulla
S
S
Grachev
D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D015992:Body Mass Index; D001835:Body Weight; D004311:Double-Blind Method; D004338:Drug Combinations; D004734:Energy Metabolism / Q000187:drug effects; D005234:Fatty Liver / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D006801:Humans; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010938:Plant Oils / Q000627:therapeutic use*; D017697:Premenopause; D016896:Treatment Outcome; D015431:Weight Loss / Q000187:drug effects; D024341:Xanthophylls / Q000627:therapeutic use*
D019440:Anti-Obesity Agents; D004338:Drug Combinations; D010938:Plant Oils; D024341:Xanthophylls; C025164:fucoxanthin